| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Tyrosinase-IN-12 targets tyrosinase, the key enzyme in melanin biosynthesis. It is a noncompetitive inhibitor of tyrosinase. By inhibiting tyrosinase, the compound reduces melanin production. It also targets reactive oxygen species (ROS) through its antioxidant and free radical scavenging activity.
|
|---|---|
| ln Vitro |
For fresh fruits and vegetables, non-competitive tyrosinase inhibitor (Tyrosinase-IN-12) (3day) may be an effective anti-browning agent [1].
Tyrosinase-IN-12 demonstrates potent in vitro tyrosinase inhibitory activity. It is a noncompetitive tyrosinase inhibitor. The compound has significant antioxidant and free radical scavenging activity and reduces ROS production with an IC50 of 25.39 ± 0.77 µM. It can be used as an anti-browning agent for fresh fruits and vegetables. |
| ln Vivo |
In vivo activity data for Tyrosinase-IN-12 are not extensively documented. Its tyrosinase inhibitory and antioxidant activities suggest potential in vivo efficacy for skin lightening and protection against oxidative stress. Its anti-browning activity suggests potential applications in food preservation. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
The in vitro enzyme assay for Tyrosinase-IN-12 involves measuring its inhibition of tyrosinase activity. Mushroom tyrosinase is commonly used as a model enzyme. The assay typically uses L-DOPA as a substrate, and the formation of dopachrome is monitored spectrophotometrically. Tyrosinase-IN-12 is incubated with the enzyme and substrate at various concentrations. The IC50 value is determined by fitting the inhibition data to a dose-response curve.
|
| Cell Assay |
Cell Viability Assay [1]
Cell Types: fresh-cut potato slices Tested Concentrations: Incubation Duration: 3 day Experimental Results: demonstrated browning inhibition effects close to those of kojic acid on fresh-cut potato slices. In vitro cellular assays for Tyrosinase-IN-12 typically use B16 melanoma cells to assess its effects on melanogenesis. Cells are treated with the compound at various concentrations. Melanin content is measured spectrophotometrically. Tyrosinase activity is assessed by measuring the oxidation of L-DOPA in cell lysates. Antioxidant activity can be assessed by measuring ROS levels using fluorescent probes. |
| Animal Protocol |
In vivo animal experiments for Tyrosinase-IN-12 are not extensively documented. As a tyrosinase inhibitor, standard in vivo studies would involve animal models of hyperpigmentation. The compound would be administered via topical or oral routes. Melanin content in skin and histopathological analysis would be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Tyrosinase-IN-12 are not extensively documented. As a small molecule, the compound is expected to have reasonable bioavailability. Its antioxidant properties may influence its stability and metabolism. Further pharmacokinetic studies are necessary to fully characterize its absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for Tyrosinase-IN-12 are not extensively available. As a research compound, it has not undergone extensive toxicological evaluation. Standard cytotoxicity assays in cell lines may have been performed to assess safety margins. Further toxicological studies would be required for clinical development.
|
| References | |
| Additional Infomation |
Tyrosinase-IN-12 is a noncompetitive tyrosinase inhibitor with significant antioxidant and free radical scavenging activity. It reduces ROS production with an IC50 of 25.39 µM. The compound is used in research on anti-browning agents for food and fruits. No clinical trials or regulatory approvals have been reported.
|
| Exact Mass |
313.044
|
|---|---|
| CAS # |
1860779-42-5
|
| PubChem CID |
6322770
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
338
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)C2=CSC(=N2)N/N=C/C3=CC=C(C=C3)Cl
|
| InChi Key |
YQKYELGBAMTOTP-VCHYOVAHSA-N
|
| InChi Code |
InChI=1S/C16H12ClN3S/c17-14-8-6-12(7-9-14)10-18-20-16-19-15(11-21-16)13-4-2-1-3-5-13/h1-11H,(H,19,20)/b18-10+
|
| Chemical Name |
N-[(E)-(4-chlorophenyl)methylideneamino]-4-phenyl-1,3-thiazol-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (159.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
